Alexander Hardy became Genentech’s Chief Executive Officer in March of 2019.
Alexander was previously head of Global Product Strategy, Roche Pharmaceuticals and has served in a number of key leadership positions across Genentech and Roche over the past 13 years.
As head of Global Product Strategy, Alexander led cross-functional teams to develop and launch new medicines and indications in more than 100 countries worldwide. He also co-chaired Roche’s late-stage portfolio committee, with direct accountability for new formulations and devices, geographic expansion, and post-marketing investments.
From 2014 to 2016, Alexander was head of Asia Pacific for Roche Pharmaceuticals, overseeing 19 countries and more than 6,000 employees. Prior to this, starting in 2005, Alexander held several senior management positions at Genentech including heading patient access services and leading commercial operations for a range of medicines and therapeutic areas from HER2-positive cancer to influenza and neuroscience.
Before joining Genentech, Alexander held leadership positions at Novartis as head of market access for Europe, country head for Denmark, and business unit head and director of strategic planning and new product development in the U.K.
Alexander completed his undergraduate education at Cambridge University in the U.K. and earned his MBA at the University of Michigan.